Intralesional or intraorbital rituximab injection for the management of biopsy-proven idiopathic orbital inflammation involving the lacrimal gland
CONCLUSION: Intralesional rituximab injection may be an effective treatment for IOI involving the lacrimal gland, achieving a 78% complete response rate in this series. Local treatment with rituximab has the potential to avoid the ocular and systemic side effects of corticosteroid and systemic immunosuppressive treatment.PMID:37995759 | DOI:10.1016/j.jcjo.2023.10.016
Source: Canadian Journal of Ophthalmology - Category: Opthalmology Authors: Hakan Demirci Suleyman Ciftci Honeylen M Tiu Teo F Yesim Demirci Roman Shinder Victor M Elner Source Type: research
More News: Canada Health | Chronic Pain | Corticosteroid Therapy | Methotrexate | Opthalmology | Pain | Pain Management | Rituxan